Bridgebio Pharma Inc. (bbio 2.5 03/15/27)
13F holders, Q2 2025 (June 30)5holders +3
3new positions
0sold out
$1.59avg. 13F price*
At the end of Q2 2025, 5 institutions reported holding Bridgebio Pharma Inc. (bbio 2.5 03/15/27) in their 13F filings, up 3 from Q1 2025. 3 opened new positions and 0 sold out. The largest holders were Graham Capital Management, L.P. ($72.8M), Nomura Holdings Inc. ($21.1M) and State of Wisconsin Investment Board ($2.5M).
- Company
- Bridgebio Pharma Inc. (bbio 2.5 03/15/27)
- CUSIP
- 10806XAB8
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $96.4M |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 60,729,135 shares bought and 100,000 shares sold, net +60,629,135 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Graham Capital Management, L.P. | 2.22% | New | 58,241,000 | $72.8M |
| Nomura Holdings Inc. | 0.17% | New | 488,135 | $21.1M |
| State of Wisconsin Investment Board | 0.01% | New | 2,000,000 | $2.5M |
| Bank of New York Mellon Corp | 0.00% | Reduce -33.3% | 200,000 | $249K |
| Jones Financial Companies LLLP | 0.00% | No change | 1,000 | $1K |
"% of holder's portfolio" is BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27)'s weight in each manager's 13F, not the share of Bridgebio Pharma Inc. (bbio 2.5 03/15/27) the manager owns.